Drug Profile


Alternative Names: Neural cell adhesion molecule mimetic

Latest Information Update: 13 Dec 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ENKAM Pharmaceuticals A/S
  • Class Antidementias; Neuroprotectants; Nootropics; Peptides
  • Mechanism of Action Fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 12 Dec 2011 Discontinued - Phase-I for Alzheimer's disease in European Union (Intranasal)
  • 12 Dec 2011 Discontinued - Phase-I for Alzheimer's disease in Switzerland (Intranasal)
  • 30 Dec 2009 FGLL is available for licensing as of 30 Dec 2009. http://www.enkam.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top